<DOC>
	<DOCNO>NCT00250367</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety risperidone ( antipsychotic medication ) versus placebo add-on therapy mood stabilizer , treatment manic episode associate bipolar disorder .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Versus Placebo add-on Therapy Mood Stabilizers , Treatment Manic Episodes Associated With Bipolar Disorder .</brief_title>
	<detailed_description>Risperidone , widely use treatment schizophrenia , show effective treatment manic mixed episode associate bipolar disorder . Antipsychotic drug like risperidone also use therapeutic agent treatment patient responsive mood stabilizer alone . This randomized , double-blind study evaluate effectiveness safety risperidone compare placebo , addition mood stabilize drug , treatment patient experience manic episode associate bipolar disorder . The study two phase : double-blind treatment phase ( 3 week ) open-label phase ( 10 week ) . To participate study , patient must in-patients minimum first 4 day double-blind treatment . During double-blind treatment phase , patient receive risperidone placebo tablet take day gradually increase dos investigator 's discretion , maximum dose 6 mg/day , continue treatment mood stabilizer ( lithium , valproate , carbamazepine ) . In open-label phase , therapy mood stabilizer continue , patient receive risperidone dosage gradually adjust achieve optimal effectiveness . The primary measure effectiveness change Young Mania Rating Scale ( YMRS ) total score baseline end double-blind treatment . Additional efficacy measure include Brief Psychiatric Rating Scale ( BPRS ) , Clinical Global Impression ( CGI ) , ( evaluate change severity disorder ) , Hamilton Depression Rating Scale ( HAMD ) . Safety assessment include incidence adverse event throughout study ; measurement vital sign ( pulse blood pressure ) evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) specify interval ; clinical laboratory test ( hematology , biochemistry , urinalysis ) study initiation , completion double-blind treatment , end study . The study hypothesis daily treatment risperidone add-on therapy provide good effectiveness addition placebo , measure Young Mania Rating Scale score , treatment manic phase bipolar disorder . Risperidone 1 mg tablet , take orally , daily ; Doses 2 mg Days 1 2 , 4 mg Days 3 4 , 6 mg ( maximum dose ) Days 5 21 . Same dose maintain 10 week open-label phase . Gradual dose adjustment allow achieve optimal effectiveness .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients hospitalize mania score &gt; =20 Young Mania Rating Scale ( YMRS ) . ( Patients symptom depression eligible ) diagnosis Bipolar Disorder accord Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) receive treatment mood stabilizer minimum 2 week prior study initiation , begin therapy mood stabilizer prior treatment study medication patient medically stable basis physical examination , medical history electrocardiogram result . Other Axis I DSMIV diagnosis ( except nicotine caffeine dependence ) history alcohol drug abuse dependence within 3 month start study seizure disorder require medication know sensitivity risperidone , lithium , valproate carbamazepine pregnant nursing female , lack adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>risperidone</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>manic episode</keyword>
</DOC>